[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355214-105":59,"doc-detail-355214-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-ex-vivo-functional-biomarker-of-treatment-response-in-pediatric-low-grade-glioma","An ex vivo functional biomarker of treatment response in pediatric low-grade glioma","","Children with subtotally resected pediatric low-grade glioma (pLGG) often receive multiple treatment lines that rarely eradicate all tumor tissue. Genomics-based biomarkers can guide targeted therapy but yield limited overall response rates, and functional precision medicine is difficult in pLGG because viable tumor tissue is challenging to maintain ex vivo. This study presents a zero-passage platform using the SLiCE system to maintain, treat, and analyze pLGG tissues for individualized testing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-ex-vivo-functional-biomarker-of-treatment-response-in-pediatric-low-grade-glioma/355214/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-ex-vivo-functional-biomarker-of-treatment-response-in-pediatric-low-grade-glioma/355214.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in pediatric low-grade glioma treatment?","Question",{"text":112,"@type":113},"Subtotally resected pLGG patients often require multiple therapy lines, yet treatments rarely eliminate the entire tumor. Genomics-based biomarkers and functional approaches both have limitations for achieving reliable individualized responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What platform is used to test pLGG tumor responses ex vivo?",{"text":117,"@type":113},"The study uses the previously validated Screening Live Cancer Explants (SLiCE) platform, which maintains and enables testing of tumor tissue outside the body using organotypic brain slice cultures (OBSCs).",{"name":119,"@type":110,"acceptedAnswer":120},"How did the tumors respond to dabrafenib and trametinib on SLiCE?",{"text":121,"@type":113},"None of the BRAF KIAA1549 fusion+ pLGG tumors were sensitive to dabrafenib. Two of three tumors showed predicted sensitivity to trametinib, while one did not, reflecting heterogeneous responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355214,1790242035,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","OPEN ACCESS  \nCitation: Artz NM, Mann B, Ebbs A, Darawsheh R, Dasari R, Adefolaju A, et al.(2026) An ex vivo functional biomarker of treatment response in pediatric low-grade glioma. PLoS One 21(3): e0331423. [https://doi](https://doi). org/10.1371/journal.pone.0331423  \nEditor: Santosh K. Patnaik, Roswell Park Cancer Institute, UNITED STATES OF AMERICA Received: October 20, 2025  \nAccepted: February 5, 2026  \nPublished: March 5, 2026  \nCopyright: © 2026 Artz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the manuscript and its Supporting  Information files.  \nFunding: This work was supported by National Center for Advancing Translational Sciences ([https://ncats.nih.gov/](https://ncats.nih.gov/)) (U01TR003715 to S.H; K12TR004416 to A.B.S) and Lineberger  \nRESEARCH ARTICLE  \nAn ex vivo functional biomarker of treatment response in pediatric low-grade glioma  \nNichole M. Artz1, Breanna Mann2,3, Aaron Ebbs4, Rami Darawsheh2, Rajaneekar Dasari3, Adebimpe Adefolaju2, Noah Bell3, Dimitri Trembath5, Dominique Higgins6, Scott Elton6, Albert Baldwin4, Shawn Hingtgen2*, David E. Kram1,4*, Andrew B. Satterlee2,3*  \n1 Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 2 Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 3 Eshelman Innovation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 4 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 5 Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 6 Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America  \n* [satterle@email.unc.edu](satterle@email.unc.edu) (ABS); [dkram@med.unc.edu](dkram@med.unc.edu) (DEK); and [hingtgen@email.unc.edu](hingtgen@email.unc.edu) (SH)  \nAbstract  \nChildren with subtotally resected pediatric low-grade glioma (pLGG) often face multiple lines of treatment, which are seldom capable of eliminating the entire tumor. Genomics-based biomarkers are often used to select targeted therapies, but this paradigm only yields overall response rates of ~50% . Functional precision medicine (FPM), where patient-specific therapeutic efficacy is evaluated by directly treating individuals’ tumor outside their body, can predict individualized drug responses for some cancers, but pLGG is notoriously difficult to maintain outside the body, limiting development of FPM for pLGG. We describe the first platform that can maintain, treat, and analyze zero-passage pLGG tumor tissue ex vivo, facilitating FPM testing. Here, we tested pLGG tumors on our previously validated Screening Live Cancer Explants (SLiCE) platform, which allows engraftment and testing of diverse CNS tumor types atop organotypic brain slice cultures (OBSCs) . After ensuring reproducible engraftment and maintenance of all three living pLGG tumor tissues on SLiCE, we measured MAPK pathway response to targeted therapies via immunoblotting. In the tested BRAF KIAA1549 fusion+ tumor, Western blot demonstrated maintenance of expected paradoxical MAPK upregulation in response to dabrafenib treatment. We then measured tumor response to targeted therapies on SLiCE. As expected, none of the BRAF KIAA1549 fusion+ pLGG tumors were sensitive to dabrafenib treatment. Two out of the three tumors demonstrated predicted sensitivity t","cbCaikB6z1iJerbI","https://ap.wps.com/l/cbCaikB6z1iJerbI","pdf",912767,13,"English","# Abstract\n# Introduction","[{\"question\":\"What problem does the study address in pediatric low-grade glioma treatment?\",\"answer\":\"Subtotally resected pLGG patients often require multiple therapy lines, yet treatments rarely eliminate the entire tumor. Genomics-based biomarkers and functional approaches both have limitations for achieving reliable individualized responses.\"},{\"question\":\"What platform is used to test pLGG tumor responses ex vivo?\",\"answer\":\"The study uses the previously validated Screening Live Cancer Explants (SLiCE) platform, which maintains and enables testing of tumor tissue outside the body using organotypic brain slice cultures (OBSCs).\"},{\"question\":\"How did the tumors respond to dabrafenib and trametinib on SLiCE?\",\"answer\":\"None of the BRAF KIAA1549 fusion+ pLGG tumors were sensitive to dabrafenib. Two of three tumors showed predicted sensitivity to trametinib, while one did not, reflecting heterogeneous responses.\"}]","An ex vivo functional biomarker of treatment response in pediatric low-grade glioma | PDF",1790116780,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d33f1534776c2275a05d66543212cb7b.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8addc23d86e76be01ce23bd7b8666b56.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65abf98c0b45e708ff1b7a7e4322a6c0.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d194725cb75d9069933f18267c3ba48.webp",980,1268]